RUA Life Sciences has released a positive AGM statement and trading update noting continued cost control and a number of positive business development updates across its divisions. While the two revenue generating divisions continue to make strong progress, we are particularly encouraged by the engagement of RUA Structural Heart and RUA Vascular with ‘major' players in these markets, which sees both divisions providing products to third-parties for testing – potentially opening new revenue strea ....
